Package 42385-929-31

{"route": ["ORAL"], "spl_id": "80228c3a-152e-4170-9469-b4e13b137bcb", "openfda": {"nui": ["N0000175463", "N0000175460", "N0000009948", "N0000190118", "N0000187064", "N0000185504", "N0000182140", "N0000182141", "N0000175656", "N0000175462", "N0000009947"], "upc": ["0342385929317"], "unii": ["JE6H2O27P8", "2T8Q726O95", "OTT9J7900I"], "rxcui": ["2001424"], "spl_set_id": ["98342153-b9de-4318-aac4-9f8d19590cd7"], "pharm_class_epc": ["Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]"], "pharm_class_moa": ["Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]"], "manufacturer_name": ["Laurus Labs Limited"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "180 TABLET, FILM COATED in 1 BOTTLE (42385-929-18)", "package_ndc": "42385-929-18", "marketing_start_date": "20200514"}, {"sample": false, "description": "30 TABLET, FILM COATED in 1 BOTTLE (42385-929-30)", "package_ndc": "42385-929-30", "marketing_start_date": "20200514"}, {"sample": false, "description": "30 TABLET, FILM COATED in 1 BOTTLE (42385-929-31)", "package_ndc": "42385-929-31", "marketing_start_date": "20200514"}, {"sample": false, "description": "180 TABLET, FILM COATED in 1 BOTTLE (42385-929-82)", "package_ndc": "42385-929-82", "marketing_start_date": "20200514"}, {"sample": false, "description": "90 TABLET, FILM COATED in 1 BOTTLE (42385-929-90)", "package_ndc": "42385-929-90", "marketing_start_date": "20200514"}, {"sample": false, "description": "90 TABLET, FILM COATED in 1 BOTTLE (42385-929-91)", "package_ndc": "42385-929-91", "marketing_start_date": "20200514"}], "brand_name": "Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate", "product_id": "42385-929_80228c3a-152e-4170-9469-b4e13b137bcb", "dosage_form": "TABLET, FILM COATED", "pharm_class": ["Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]", "Non-Nucleoside Analog [EXT]", "Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Nucleosides [CS]"], "product_ndc": "42385-929", "generic_name": "Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate", "labeler_name": "Laurus Labs Limited", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate", "active_ingredients": [{"name": "EFAVIRENZ", "strength": "400 mg/1"}, {"name": "LAMIVUDINE", "strength": "300 mg/1"}, {"name": "TENOFOVIR DISOPROXIL FUMARATE", "strength": "300 mg/1"}], "application_number": "ANDA213038", "marketing_category": "ANDA", "marketing_start_date": "20200514", "listing_expiration_date": "20261231"}